The traditional treatment has inevitable drawbacks of nonspecific lymph targeting, poor therapeutic efficiency and residual metastatic for advanced cancer patients with lymph node metastases. To overcome these shortcomings, we prepare a nano-carrier drug delivery system. Photosensitizer hematoporphyrin monomethyl ether (HMME)-loaded poly (n-butylcyanoacrylate) nanoparticles (PBCA-NPs) was prepared successfully. The particle size was approximately 160 nm, the envelopment rate was 87.9%, and the drug loading rate was about 13.4%. The drug release study in vitro showed that the cumulative release rates of HMME-PBCA-NPs group was much less than free HMME group. The drug distribution in different tissues showed that the peak-reach time was 3 h in free HMME group and 6 h in nanoparticles group. All of these results confirmed the slow release characteristic of nanoparticles. In lymph node tissues, the HMME concentrations in HMME-PBCA-NPs group were much higher than those of the free HMME group at any time points we tested, in which the maximum difference concentration of HMME appeared at 6 h (1.2884 ± 0.04695 vs. 0.0438 ± 0.00558 µg/mg) after drug delivery. The mesenteric lymph nodes of rabbits were enlarged obviously in the NP group than in free HMME group at 6 h after drug delivery. All of these results confirmed the slow release characteristic and the lymphatic targeting characteristic of nanoparticles. In summary, we developed a lymphatic targeting nanoparticles drug delivery system successfully, which showed perfect lymph targeting and has the potential to be a new therapy strategy for advanced cancer patients with lymph node metastasis.